Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Interplay between Pathophysiological Pathways in Early-Onset Severe Preeclampsia Unveiled by Metabolomics

  • Youssef, Lina|||0000-0002-0554-5507
  • Crovetto, Francesca|||0000-0003-0140-7411
  • Simoes, Rui Vasco|||0000-0001-7574-4723
  • Miranda, Jezid|||0000-0003-0372-8374
  • Paules, Cristina|||0000-0001-6795-0367
  • Blasco Pelicano, Miquel|||0000-0003-0789-7992
  • Palomo, Marta|||0000-0002-3261-6577
  • García Calderó, Héctor|||0000-0002-8801-6394
  • Tura-Ceide, Olga|||0000-0003-4334-9790
  • Dantas, A. P|||0000-0001-8514-4094
  • Hernández-Gea, Virginia|||0000-0001-7937-984X
  • Herrero, Pol|||0000-0002-8746-7214
  • Canela, Núria|||0000-0003-0261-2396
  • Campistol Plana, Josep M.|||0000-0002-6841-1119
  • Garcia Pagan, Joan Carles
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Gratacós, Eduard|||0000-0002-7405-7224
  • Crispi, Fatima|||0000-0002-7422-5240
Introduction: Preeclampsia is a multi-system disorder unique to pregnancy responsible for a great part of maternal and perinatal morbidity and mortality. The precise pathogenesis of this complex disorder is still unrevealed. Methods: We examined the pathophysiological pathways involved in early-onset preeclampsia, a specific subgroup representing its most severe presentation, using LC-MS/MS metabolomic analysis based on multi-level extraction of lipids and small metabolites from maternal blood samples, collected at the time of diagnosis from 14 preeclamptic and six matched healthy pregnancies. Statistical analysis comprised multivariate and univariate approaches with the application of over representation analysis to identify differential pathways. Results: A clear difference between preeclamptic and control pregnancies was observed in principal component analysis. Supervised multivariate analysis using orthogonal partial least square discriminant analysis provided a robust model with goodness of fit (R X = 0.91, p = 0.002) and predictive ability (Q Y = 0.72, p < 0.001). Finally, univariate analysis followed by 5% false discovery rate correction indicated 82 metabolites significantly altered, corresponding to six overrepresented pathways: (1) aminoacyl-tRNA biosynthesis; (2) arginine biosynthesis; (3) alanine, aspartate and glutamate metabolism; (4) D-glutamine and D-glutamate metabolism; (5) arginine and proline metabolism; and (6) histidine metabolism. Conclusion: Metabolomic analysis focusing specifically on the early-onset severe form of preeclampsia reveals the interplay between pathophysiological pathways involved in this form. Future studies are required to explore new therapeutic approaches targeting these altered metabolic pathways in early-onset preeclampsia.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Complement and coagulation cascades activation is the main pathophysiological pathway in early-onset severe preeclampsia revealed by maternal proteomics

  • Youssef, Lina|||0000-0002-0554-5507
  • Miranda, Jezid|||0000-0003-0372-8374
  • Blasco Pelicano, Miquel|||0000-0003-0789-7992
  • Paules, Cristina|||0000-0001-6795-0367
  • Crovetto, Francesca|||0000-0003-0140-7411
  • Palomo, Marta|||0000-0002-3261-6577
  • Torramade Moix, Sergi
  • García Calderó, Héctor|||0000-0002-8801-6394
  • Tura-Ceide, Olga|||0000-0003-4334-9790
  • Dantas, A. P.|||0000-0001-8514-4094
  • Hernández-Gea, Virginia|||0000-0001-7937-984X
  • Herrero, Pol|||0000-0002-8746-7214
  • Canela, Núria|||0000-0003-0261-2396
  • Campistol Plana, Josep M.|||0000-0002-6841-1119
  • Garcia Pagan, Joan Carles
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Gratacós, Eduard|||0000-0002-7405-7224
  • Crispi, Fatima|||0000-0002-7422-5240
Preeclampsia is a pregnancy-specific multisystem disorder and a leading cause of maternal and perinatal morbidity and mortality. The exact pathogenesis of this multifactorial disease remains poorly defined. We applied proteomics analysis on maternal blood samples collected from 14 singleton pregnancies with early-onset severe preeclampsia and 6 uncomplicated pregnancies to investigate the pathophysiological pathways involved in this specific subgroup of preeclampsia. Maternal blood was drawn at diagnosis for cases and at matched gestational age for controls. LC-MS/MS proteomics analysis was conducted, and data were analyzed by multivariate and univariate statistical approaches with the identification of differential pathways by exploring the global human protein-protein interaction network. The unsupervised multivariate analysis (the principal component analysis) showed a clear difference between preeclamptic and uncomplicated pregnancies. The supervised multivariate analysis using orthogonal partial least square discriminant analysis resulted in a model with goodness of fit (RX = 0.99, p < 0.001) and a strong predictive ability (QY = 0.8, p < 0.001). By univariate analysis, we found 17 proteins statistically different after 5% FDR correction (q-value < 0.05). Pathway enrichment analysis revealed 5 significantly enriched pathways whereby the activation of the complement and coagulation cascades was on top (p = 3.17e-07). To validate these results, we assessed the deposits of C5b-9 complement complex and on endothelial cells that were exposed to activated plasma from an independent set of 4 cases of early-onset severe preeclampsia and 4 uncomplicated pregnancies. C5b-9 and Von Willbrand factor deposits were significantly higher in early-onset severe preeclampsia. Future studies are warranted to investigate potential therapeutic targets for early-onset severe preeclampsia within the complement and coagulation pathway.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Circulating Cell Biomarkers in Pulmonary Arterial Hypertension, Relationship with Clinical Heterogeneity and Therapeutic Response

  • Tura-Ceide, Olga|||0000-0003-4334-9790
  • Blanco, Isabel|||0000-0001-9452-3432
  • Garcia-Lucio, Jéssica
  • del Pozo, Roberto
  • García, Agustín Roberto
  • Ferrer, Elisabet|||0000-0002-0900-5436
  • Crespo García, Isabel
  • Rodríguez-Chiaradia, Diego A.|||0000-0002-8566-4011
  • Simeón-Aznar, Carmen Pilar|||0000-0003-3390-9029
  • López-Meseguer, Manuel|||0000-0003-2650-9238
  • Martín-Ontiyuelo, Clara
  • Peinado, Víctor I.
  • Barberà i Mir, Joan Albert|||0000-0003-1469-4990
Background: Endothelial dysfunction is central to PAH. In this study, we simultaneously analysed circulating levels of endothelial microvesicles (EMVs) and progenitor cells (PCs) in PAH and in controls, as biomarkers of pulmonary endothelial integrity and evaluated differences among PAH subtypes and as a response to treatment. Methods: Forty-seven controls and 144 patients with PAH (52 idiopathic, 9 heritable, 31 associated with systemic sclerosis, 15 associated with other connective tissue diseases, 20 associated with HIV and 17 associated with portal hypertension) were evaluated. Forty-four patients with scleroderma and 22 with HIV infection, but without PAH, were also studied. Circulating levels of EMVs, total (CD31 + CD42b -) and activated (CD31 + CD42b - CD62E +), as well as circulating PCs (CD34 + CD133 + CD45 low) were measured by flow cytometry and the EMVs/PCs ratio was computed. In treatment-naïve patients, measurements were repeated after 3 months of PAH therapy. Results: Patients with PAH showed higher numbers of EMVs and a lower percentage of PCs, compared with healthy controls. The EMV/PC ratio was increased in PAH patients, and in patients with SSc or HIV without PAH. After starting PAH therapy, individual changes in EMVs and PCs were variable, without significant differences being observed as a group. Conclusion: PAH patients present disturbed vascular homeostasis, reflected in changes in circulating EMV and PC levels, which are not restored with PAH targeted therapy. Combined measurement of circulating EMVs and PCs could be foreseen as a potential biomarker of endothelial dysfunction in PAH.